Citi Downgrades Alexion Pharmaceuticals (ALXN) to Neutral
Tweet
Share
E-mailGet Alerts ALXN Hot Sheet
Price: $182.01 --0%
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 9 | New: 16
Rating Summary:
10 Buy, 25 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 9 | New: 16
Join SI Premium – FREE
Citi analyst Mohit Bansal downgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Buy to Neutral with a price target of $175.00 (from $162.00).
For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.
Shares of Alexion Pharmaceuticals closed at $120.98 yesterday.
You May Also Be Interested In
- BofA Securities Upgrades Etsy (ETSY) to Buy, 'Still Room to Run'
- Citi cuts TJX Companies rating to Neutral, lowers price target
- FOX Corp. (FOXA) PT Raised to $93 at Wolfe Research
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
